kallikrein related peptidase 10Genealiases: NES1 · PRSSL1
Q-omics provides the consensus-scored KLK10 profile across patient tissues and cancer cell-line models. KLK10 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KLK10 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, KLK10 RNA expression shows 13,155 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, COAD, and THYM as cancer lineages where KLK10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLK10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLK10 survival associations across molecular data types. KLK10 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLK10 RNA expression–survival associations across cancer types. High KLK10 expression shows unfavorable associations in KIRC, PAAD, KIRP, UCS and SKCM, but favorable associations in ACC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KLK10 RNA expression.
This table summarizes KLK10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for KLK10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLK10 shows lower tumor expression in LUAD, BRCA and KICH and higher tumor expression in COAD, THCA and PAAD. The COAD box plot shows higher KLK10 RNA expression in tumor versus normal tissue (log2 FC = +5.050, t-test p < 0.001).
This table shows molecular features associated with KLK10 in patient tissues and cancer cell lines. In patient samples, KLK10 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLK10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and OVARY.
